Literature DB >> 22844265

Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds.

Andrea Torti1, Andrea Lossani, Lida Savi, Federico Focher, George Edward Wright, Neal Curtis Brown, Wei-Chu Xu.   

Abstract

Based on the finding that aerobic Gram-positive antibacterials that inhibit DNA polymerase IIIC (pol IIIC) were potent inhibitors of the growth of anaerobic Clostridium difficile (CD) strains, we chose to clone and express the gene for pol IIIC from this organism. The properties of the recombinant enzyme are similar to those of related pol IIICs from Gram-positive aerobes, e.g. B. subtilis. Inhibitors of the CD enzyme also inhibited B. subtilis pol IIIC, and were competitive with respect to the cognate substrate 2'-deoxyguanosine 5'-triphosphate (dGTP). Significantly, several of these inhibitors of the CD pol IIIC had potent activity against the growth of CD clinical isolates in culture.

Entities:  

Year:  2011        PMID: 22844265      PMCID: PMC3404731          DOI: 10.2174/157340811798807597

Source DB:  PubMed          Journal:  Curr Enzym Inhib        ISSN: 1573-4080


  20 in total

1.  Structure of PolC reveals unique DNA binding and fidelity determinants.

Authors:  Ronald J Evans; Douglas R Davies; James M Bullard; Jeffrey Christensen; Louis S Green; Joseph W Guiles; Janice D Pata; Wendy K Ribble; Nebojsa Janjic; Thale C Jarvis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

Review 2.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

3.  The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome.

Authors:  Mohammed Sebaihia; Brendan W Wren; Peter Mullany; Neil F Fairweather; Nigel Minton; Richard Stabler; Nicholas R Thomson; Adam P Roberts; Ana M Cerdeño-Tárraga; Hongmei Wang; Matthew T G Holden; Anne Wright; Carol Churcher; Michael A Quail; Stephen Baker; Nathalie Bason; Karen Brooks; Tracey Chillingworth; Ann Cronin; Paul Davis; Linda Dowd; Audrey Fraser; Theresa Feltwell; Zahra Hance; Simon Holroyd; Kay Jagels; Sharon Moule; Karen Mungall; Claire Price; Ester Rabbinowitsch; Sarah Sharp; Mark Simmonds; Kim Stevens; Louise Unwin; Sally Whithead; Bruno Dupuy; Gordon Dougan; Bart Barrell; Julian Parkhill
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

4.  Antibody to B. subtilis DNA polymerase III: use in enzyme purification and examination of homology among replication-specific DNA polymerases.

Authors:  M H Barnes; N C Brown
Journal:  Nucleic Acids Res       Date:  1979-03       Impact factor: 16.971

5.  Inhibition of Bacillus subtilis DNA polymerase III by arylhydrazinopyrimidines. Novel properties of 2-thiouracil derivatives.

Authors:  G E Wright; N C Brown
Journal:  Biochim Biophys Acta       Date:  1976-04-15

6.  Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils.

Authors:  G E Wright; N C Brown
Journal:  J Med Chem       Date:  1980-01       Impact factor: 7.446

Review 7.  Update on the changing epidemiology of Clostridium difficile-associated disease.

Authors:  Lynne V McFarland
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-01

8.  Removal of DnaK contamination during fusion protein purifications.

Authors:  Daniela V Rial; Eduardo A Ceccarelli
Journal:  Protein Expr Purif       Date:  2002-08       Impact factor: 1.650

9.  Characterization and overexpression of the gene encoding Staphylococcus aureus DNA polymerase III.

Authors:  D F Pacitti; M H Barnes; D H Li; N C Brown
Journal:  Gene       Date:  1995-11-07       Impact factor: 3.688

10.  Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005.

Authors:  Marya D Zilberberg; Andrew F Shorr; Marin H Kollef
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

View more
  4 in total

1.  A novel agent effective against Clostridium difficile infection.

Authors:  Sofya Dvoskin; Wei-Chu Xu; Neal C Brown; Ivan B Yanachkov; Milka Yanachkova; George E Wright
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

2.  Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile.

Authors:  Erika van Eijk; Ilse M Boekhoud; Ed J Kuijper; Ingrid M J G Bos-Sanders; George Wright; Wiep Klaas Smits
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 3.  DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.

Authors:  Erika van Eijk; Bert Wittekoek; Ed J Kuijper; Wiep Klaas Smits
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

Review 4.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.